View Future GrowthNirman Agri Genetics 過去の業績過去 基準チェック /16Nirman Agri Geneticsは、平均年間35.8%の収益成長を遂げていますが、 Biotechs業界の収益は、年間 成長しています。収益は、平均年間13.4% 39.4%収益成長率で 成長しています。 Nirman Agri Geneticsの自己資本利益率は13.8%であり、純利益率は9%です。主要情報35.83%収益成長率30.04%EPS成長率Biotechs 業界の成長5.13%収益成長率39.43%株主資本利益率13.80%ネット・マージン8.96%前回の決算情報31 Mar 2026最近の業績更新分析記事 • Jun 08There Might Be More To Nirman Agri Genetics' (NSE:NIRMAN) Story Than Just Weak EarningsShareholders didn't appear too concerned by Nirman Agri Genetics Limited's ( NSE:NIRMAN ) weak earnings. We did some...Reported Earnings • Jun 03Full year 2026 earnings released: EPS: ₹21.98 (vs ₹31.57 in FY 2025)Full year 2026 results: EPS: ₹21.98 (down from ₹31.57 in FY 2025). Revenue: ₹1.97b (down 17% from FY 2025). Net income: ₹176.1m (down 30% from FY 2025). Profit margin: 9.0% (down from 11% in FY 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.お知らせ • May 27Nirman Agri Genetics Limited to Report Q4, 2026 Results on May 30, 2026Nirman Agri Genetics Limited announced that they will report Q4, 2026 results on May 30, 2026分析記事 • Nov 28We Don’t Think Nirman Agri Genetics' (NSE:NIRMAN) Earnings Should Make Shareholders Too ComfortableInvestors appear disappointed with Nirman Agri Genetics Limited's ( NSE:NIRMAN ) recent earnings, despite the decent...Reported Earnings • Nov 20First half 2026 earnings released: EPS: ₹18.20 (vs ₹16.46 in 1H 2025)First half 2026 results: EPS: ₹18.20 (up from ₹16.46 in 1H 2025). Revenue: ₹1.46b (up 30% from 1H 2025). Net income: ₹145.8m (up 27% from 1H 2025). Profit margin: 10.0% (in line with 1H 2025).お知らせ • Nov 14Nirman Agri Genetics Limited to Report First Half, 2026 Results on Nov 14, 2025Nirman Agri Genetics Limited announced that they will report first half, 2026 results on Nov 14, 2025すべての更新を表示Recent updatesBuy Or Sell Opportunity • Jun 09Now 28% overvaluedOver the last 90 days, the stock has fallen 9.5% to ₹45.25. The fair value is estimated to be ₹35.31, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has grown by 30%.分析記事 • Jun 08There Might Be More To Nirman Agri Genetics' (NSE:NIRMAN) Story Than Just Weak EarningsShareholders didn't appear too concerned by Nirman Agri Genetics Limited's ( NSE:NIRMAN ) weak earnings. We did some...Reported Earnings • Jun 03Full year 2026 earnings released: EPS: ₹21.98 (vs ₹31.57 in FY 2025)Full year 2026 results: EPS: ₹21.98 (down from ₹31.57 in FY 2025). Revenue: ₹1.97b (down 17% from FY 2025). Net income: ₹176.1m (down 30% from FY 2025). Profit margin: 9.0% (down from 11% in FY 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (57% accrual ratio). Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Market cap is less than US$10m (₹389.7m market cap, or US$4.10m). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Paying a dividend despite having no free cash flows.お知らせ • May 27Nirman Agri Genetics Limited to Report Q4, 2026 Results on May 30, 2026Nirman Agri Genetics Limited announced that they will report Q4, 2026 results on May 30, 2026Buy Or Sell Opportunity • Apr 02Now 21% overvaluedOver the last 90 days, the stock has fallen 31% to ₹42.60. The fair value is estimated to be ₹35.31, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 78% over the last year. Earnings per share has grown by 38%.Valuation Update With 7 Day Price Move • Dec 04Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₹71.05, the stock trades at a trailing P/E ratio of 2x. Average trailing P/E is 91x in the Biotechs industry in India. Total loss to shareholders of 82% over the past year.分析記事 • Nov 28We Don’t Think Nirman Agri Genetics' (NSE:NIRMAN) Earnings Should Make Shareholders Too ComfortableInvestors appear disappointed with Nirman Agri Genetics Limited's ( NSE:NIRMAN ) recent earnings, despite the decent...Reported Earnings • Nov 20First half 2026 earnings released: EPS: ₹18.20 (vs ₹16.46 in 1H 2025)First half 2026 results: EPS: ₹18.20 (up from ₹16.46 in 1H 2025). Revenue: ₹1.46b (up 30% from 1H 2025). Net income: ₹145.8m (up 27% from 1H 2025). Profit margin: 10.0% (in line with 1H 2025).お知らせ • Nov 14Nirman Agri Genetics Limited to Report First Half, 2026 Results on Nov 14, 2025Nirman Agri Genetics Limited announced that they will report first half, 2026 results on Nov 14, 2025Valuation Update With 7 Day Price Move • Nov 03Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹95.05, the stock trades at a trailing P/E ratio of 3x. Average trailing P/E is 104x in the Biotechs industry in India. Total loss to shareholders of 72% over the past year.New Risk • Oct 29New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹843.4m (US$9.56m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.8% average weekly change). High level of non-cash earnings (97% accrual ratio). Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Market cap is less than US$10m (₹843.4m market cap, or US$9.56m). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (11% net profit margin).Board Change • Oct 11High number of new directorsNon-Executive Director Sagar Chavan was the last director to join the board, commencing their role in 2025.分析記事 • Oct 09A Piece Of The Puzzle Missing From Nirman Agri Genetics Limited's (NSE:NIRMAN) 31% Share Price ClimbNirman Agri Genetics Limited ( NSE:NIRMAN ) shareholders are no doubt pleased to see that the share price has bounced...Valuation Update With 7 Day Price Move • Oct 02Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₹170, the stock trades at a trailing P/E ratio of 4.7x. Average trailing P/E is 61x in the Biotechs industry in India. Total loss to shareholders of 50% over the past year.New Risk • Sep 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.2% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Profit margins are more than 30% lower than last year (11% net profit margin). Market cap is less than US$100m (₹1.12b market cap, or US$12.6m).Buy Or Sell Opportunity • Sep 18Now 20% overvaluedOver the last 90 days, the stock has fallen 1.5% to ₹200. The fair value is estimated to be ₹166, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 65% over the last 3 years. Earnings per share has grown by 40%.Valuation Update With 7 Day Price Move • Sep 12Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹164, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 63x in the Biotechs industry in India. Total loss to shareholders of 61% over the past year.お知らせ • Sep 10Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2025Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2025, at 13:00 Indian Standard Time.New Risk • Aug 24New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹872.7m market cap, or US$10.00m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Share price has been volatile over the past 3 months (7.3% average weekly change). Profit margins are more than 30% lower than last year (11% net profit margin).New Risk • Aug 04New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹873.9m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹873.9m market cap, or US$9.97m). Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Profit margins are more than 30% lower than last year (11% net profit margin).Valuation Update With 7 Day Price Move • Jul 30Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹148, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 55x in the Biotechs industry in India. Total loss to shareholders of 60% over the past year.New Risk • Jul 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Profit margins are more than 30% lower than last year (11% net profit margin). Market cap is less than US$100m (₹1.05b market cap, or US$12.2m).分析記事 • Jul 19Positive Sentiment Still Eludes Nirman Agri Genetics Limited (NSE:NIRMAN) Following 26% Share Price SlumpUnfortunately for some shareholders, the Nirman Agri Genetics Limited ( NSE:NIRMAN ) share price has dived 26% in the...分析記事 • Jul 19Positive Sentiment Still Eludes Nirman Agri Genetics Limited (NSE:NIRMAN) Following 26% Share Price SlumpUnfortunately for some shareholders, the Nirman Agri Genetics Limited ( NSE:NIRMAN ) share price has dived 26% in the...Buy Or Sell Opportunity • Jun 23Now 21% overvaluedOver the last 90 days, the stock has fallen 7.7% to ₹205. The fair value is estimated to be ₹169, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 65% over the last 3 years. Earnings per share has grown by 40%.Valuation Update With 7 Day Price Move • Jun 10Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₹204, the stock trades at a trailing P/E ratio of 5.6x. Average trailing P/E is 49x in the Biotechs industry in India. Total returns to shareholders of 9.9% over the past year.Board Change • May 14High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. MD & Director Pranav Bagal is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Apr 09Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹260, the stock trades at a trailing P/E ratio of 7.2x. Average trailing P/E is 48x in the Biotechs industry in India. Total returns to shareholders of 35% over the past year.New Risk • Apr 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.7% average weekly change). Minor Risks Profit margins are more than 30% lower than last year (11% net profit margin). Market cap is less than US$100m (₹1.36b market cap, or US$15.9m).分析記事 • Mar 29Investors Give Nirman Agri Genetics Limited (NSE:NIRMAN) Shares A 27% HidingTo the annoyance of some shareholders, Nirman Agri Genetics Limited ( NSE:NIRMAN ) shares are down a considerable 27...Valuation Update With 7 Day Price Move • Mar 25Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹222, the stock trades at a trailing P/E ratio of 6.1x. Average trailing P/E is 52x in the Biotechs industry in India. Total returns to shareholders of 28% over the past year.Buy Or Sell Opportunity • Mar 24Now 21% overvaluedOver the last 90 days, the stock has fallen 46% to ₹211. The fair value is estimated to be ₹175, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 65% over the last 3 years. Earnings per share has grown by 40%.分析記事 • Mar 19Calculating The Intrinsic Value Of Nirman Agri Genetics Limited (NSE:NIRMAN)Key Insights Using the 2 Stage Free Cash Flow to Equity, Nirman Agri Genetics fair value estimate is ₹175 Current share...Valuation Update With 7 Day Price Move • Mar 05Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹227, the stock trades at a trailing P/E ratio of 6.3x. Average trailing P/E is 47x in the Biotechs industry in India. Total returns to shareholders of 11% over the past year.Valuation Update With 7 Day Price Move • Feb 12Investor sentiment deteriorates as stock falls 26%After last week's 26% share price decline to ₹263, the stock trades at a trailing P/E ratio of 7.3x. Average trailing P/E is 54x in the Biotechs industry in India. Total returns to shareholders of 1.2% over the past year.分析記事 • Feb 12Nirman Agri Genetics Limited (NSE:NIRMAN) Stock's 28% Dive Might Signal An Opportunity But It Requires Some ScrutinyNirman Agri Genetics Limited ( NSE:NIRMAN ) shares have had a horrible month, losing 28% after a relatively good period...New Risk • Feb 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Profit margins are more than 30% lower than last year (11% net profit margin). Market cap is less than US$100m (₹1.72b market cap, or US$19.8m).New Risk • Feb 06New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 11% Last year net profit margin: 16% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (11% net profit margin). Market cap is less than US$100m (₹2.13b market cap, or US$24.3m).Reported Earnings • Feb 06Third quarter 2025 earnings released: EPS: ₹8.40 (vs ₹5.60 in 3Q 2024)Third quarter 2025 results: EPS: ₹8.40 (up from ₹5.60 in 3Q 2024). Revenue: ₹610.7m (up 199% from 3Q 2024). Net income: ₹67.3m (up 101% from 3Q 2024). Profit margin: 11% (down from 16% in 3Q 2024). The decrease in margin was driven by higher expenses.お知らせ • Jan 09+ 1 more updateNirman Agri Genetics Limited Announces the Resignation of Sandipan Baburao Bhawar as Chief Financial OfficerNirman Agri Genetics Limited informed that Mr. Sandipan Baburao Bhawar has tendered his resignation from the Post of Chief Financial Officer (CFO) and KMP of the Company effective from January 8, 2025 (after the closing of business hours) on account of reasons as mentioned in resignation letter attached herewith. The Company is in the process of appointing a new Chief Financial Officer and the same will be communicated to the Stock Exchange in due course.分析記事 • Jan 08Should You Be Adding Nirman Agri Genetics (NSE:NIRMAN) To Your Watchlist Today?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Board Change • Jan 02High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. MD & Director Pranav Bagal is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 19High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. MD & Director Pranav Bagal is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 15Second quarter 2025 earnings released: EPS: ₹8.01 (vs ₹5.60 in 2Q 2024)Second quarter 2025 results: EPS: ₹8.01 (up from ₹5.60 in 2Q 2024). Revenue: ₹620.9m (up 204% from 2Q 2024). Net income: ₹64.2m (up 92% from 2Q 2024). Profit margin: 10% (down from 16% in 2Q 2024). The decrease in margin was driven by higher expenses.お知らせ • Sep 27Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2024Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2024, at 12:00 Indian Standard Time.Valuation Update With 7 Day Price Move • Sep 20Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹346, the stock trades at a trailing P/E ratio of 15.2x. Average trailing P/E is 36x in the Biotechs industry in India. Total returns to shareholders of 99% over the past year.Reported Earnings • Aug 15First quarter 2025 earnings releasedFirst quarter 2025 results: EPS: ₹8.45. Net income: ₹50.4m (up ₹50.4m from 1Q 2024).Valuation Update With 7 Day Price Move • Aug 14Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹439, the stock trades at a trailing P/E ratio of 25.2x. Average trailing P/E is 29x in the Biotechs industry in India. Total returns to shareholders of 219% over the past year.分析記事 • Aug 13Here's Why We Think Nirman Agri Genetics (NSE:NIRMAN) Might Deserve Your Attention TodayThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Valuation Update With 7 Day Price Move • Jul 19Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹439, the stock trades at a trailing P/E ratio of 25.1x. Average trailing P/E is 49x in the Biotechs industry in India. Total returns to shareholders of 124% over the past year.分析記事 • Jul 03Nirman Agri Genetics Limited (NSE:NIRMAN) Stock Rockets 47% But Many Are Still Ignoring The CompanyThe Nirman Agri Genetics Limited ( NSE:NIRMAN ) share price has done very well over the last month, posting an...Valuation Update With 7 Day Price Move • Jul 01Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹249, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 44x in the Biotechs industry in India. Total returns to shareholders of 87% over the past year.New Risk • Jun 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.6% average weekly change). Minor Risk Market cap is less than US$100m (₹1.10b market cap, or US$13.2m).Valuation Update With 7 Day Price Move • Jun 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹185, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 44x in the Biotechs industry in India. Total returns to shareholders of 70% over the past year.お知らせ • Jun 01Nirman Agri Genetics Limited to Report Second Half, 2024 Results on May 30, 2024Nirman Agri Genetics Limited announced that they will report second half, 2024 results on May 30, 2024Reported Earnings • May 29Full year 2024 earnings released: EPS: ₹17.46 (vs ₹6.72 in FY 2023)Full year 2024 results: EPS: ₹17.46 (up from ₹6.72 in FY 2023). Revenue: ₹633.4m (up 121% from FY 2023). Net income: ₹104.0m (up 160% from FY 2023). Profit margin: 16% (up from 14% in FY 2023). The increase in margin was driven by higher revenue.Valuation Update With 7 Day Price Move • Apr 22Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹223, the stock trades at a trailing P/E ratio of 33.2x. Average trailing P/E is 35x in the Biotechs industry in India. Total returns to shareholders of 204% over the past year.お知らせ • Apr 19Nirman Agri Genetics Limited Receives License from Department of Agriculture, Government of TelanganaNirman Agri Genetics Limited informed to the Stakeholders that the Company has been granted with License from the Government of Telangana to carry on the business of a dealer in seeds for various purposes in the State of Telangana. It will help in expanding and tapping new geographical markets. This license will magnificently support to increase revenues. Name of the regulatory or licensing authority: Department of Agriculture, Government of Telangana. Brief details of the approval/license: The Company has been granted license to sell, export, import and store the Agriculture Seeds for the various purposes in the State of Telangana. Access to this License will help in dealing of Paddy seeds in the State of Telangana. Period for which such license is valid: 5 years (From February 26, 2024 to February 24, 2029).Valuation Update With 7 Day Price Move • Mar 28Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹178, the stock trades at a trailing P/E ratio of 26.5x. Average trailing P/E is 32x in the Biotechs industry in India. Total returns to shareholders of 85% over the past year.Valuation Update With 7 Day Price Move • Mar 13Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹190, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 33x in the Biotechs industry in India.Valuation Update With 7 Day Price Move • Dec 12Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹258, the stock trades at a trailing P/E ratio of 38.4x. Average trailing P/E is 53x in the Biotechs industry in India.Valuation Update With 7 Day Price Move • Oct 12Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹214, the stock trades at a trailing P/E ratio of 31.8x. Average trailing P/E is 32x in the Biotechs industry in India.お知らせ • Sep 13Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2023Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2023, at 12:00 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone Financial Statements of the Company for the Financial Year ended 31st March, 2023 and the Reports of the Board of Directors and Auditors thereon; to Re-appoint Mr. Avinash Bhimrao Bagal, Non-Executive Non-Independent Director, who retires by rotation and being eligible, offers himself for re-appointment; to Approve the Appointment of M/s. Devendra C Belan & Associates, Chartered Accountants (ICAI Firm Registration Number: 126495W) as the Statutory Auditor of the Company for a period of 5 years; i.e. from the conclusion of this Annual General Meeting till the conclusion of Next Annual General Meeting from this Annual General Meeting; and to discuss other matters.Valuation Update With 7 Day Price Move • Aug 24Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹178, the stock trades at a trailing P/E ratio of 26.5x. Average trailing P/E is 35x in the Biotechs industry in India.New Risk • Aug 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹815.4m (US$9.85m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). High level of non-cash earnings (28% accrual ratio). Market cap is less than US$10m (₹815.4m market cap, or US$9.85m). Minor Risk Revenue is less than US$5m (₹286m revenue, or US$3.5m).Valuation Update With 7 Day Price Move • Aug 07Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹161, the stock trades at a trailing P/E ratio of 24x. Average trailing P/E is 37x in the Biotechs industry in Asia.Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹147, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 38x in the Biotechs industry in Asia.Valuation Update With 7 Day Price Move • Jun 01Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹96.90, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 39x in the Biotechs industry in Asia.Valuation Update With 7 Day Price Move • Apr 27Investor sentiment improves as stock rises 26%After last week's 26% share price gain to ₹76.75, the stock trades at a trailing P/E ratio of 17.9x. Average trailing P/E is 17x in the Biotechs industry in India.Valuation Update With 7 Day Price Move • Apr 12Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹67.70, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 17x in the Biotechs industry in India.Board Change • Mar 31High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. MD & Director Pranav Bagal is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.収支内訳Nirman Agri Genetics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NSEI:NIRMAN 収益、費用、利益 ( )INR Millions日付収益収益G+A経費研究開発費31 Mar 261,96617610031 Dec 252,34423219030 Sep 252,70328422030 Jun 252,59327523031 Mar 252,36525323031 Dec 241,94021518030 Sep 241,51817919030 Jun 241,02713616031 Mar 2463310415031 Mar 232864010031 Mar 22135265031 Mar 2166130質の高い収益: NIRMAN 非現金収入 のレベルが高いです。利益率の向上: NIRMANの現在の純利益率 (9%)は、昨年(10.7%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: NIRMANの収益は過去 5 年間で年間35.8%増加しました。成長の加速: NIRMANは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: NIRMANは過去 1 年間で収益成長率がマイナス ( -30.4% ) となったため、 Biotechs業界平均 ( 4.3% ) と比較することが困難です。株主資本利益率高いROE: NIRMANの 自己資本利益率 ( 13.8% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/14 22:24終値2026/06/12 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Nirman Agri Genetics Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
分析記事 • Jun 08There Might Be More To Nirman Agri Genetics' (NSE:NIRMAN) Story Than Just Weak EarningsShareholders didn't appear too concerned by Nirman Agri Genetics Limited's ( NSE:NIRMAN ) weak earnings. We did some...
Reported Earnings • Jun 03Full year 2026 earnings released: EPS: ₹21.98 (vs ₹31.57 in FY 2025)Full year 2026 results: EPS: ₹21.98 (down from ₹31.57 in FY 2025). Revenue: ₹1.97b (down 17% from FY 2025). Net income: ₹176.1m (down 30% from FY 2025). Profit margin: 9.0% (down from 11% in FY 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
お知らせ • May 27Nirman Agri Genetics Limited to Report Q4, 2026 Results on May 30, 2026Nirman Agri Genetics Limited announced that they will report Q4, 2026 results on May 30, 2026
分析記事 • Nov 28We Don’t Think Nirman Agri Genetics' (NSE:NIRMAN) Earnings Should Make Shareholders Too ComfortableInvestors appear disappointed with Nirman Agri Genetics Limited's ( NSE:NIRMAN ) recent earnings, despite the decent...
Reported Earnings • Nov 20First half 2026 earnings released: EPS: ₹18.20 (vs ₹16.46 in 1H 2025)First half 2026 results: EPS: ₹18.20 (up from ₹16.46 in 1H 2025). Revenue: ₹1.46b (up 30% from 1H 2025). Net income: ₹145.8m (up 27% from 1H 2025). Profit margin: 10.0% (in line with 1H 2025).
お知らせ • Nov 14Nirman Agri Genetics Limited to Report First Half, 2026 Results on Nov 14, 2025Nirman Agri Genetics Limited announced that they will report first half, 2026 results on Nov 14, 2025
Buy Or Sell Opportunity • Jun 09Now 28% overvaluedOver the last 90 days, the stock has fallen 9.5% to ₹45.25. The fair value is estimated to be ₹35.31, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has grown by 30%.
分析記事 • Jun 08There Might Be More To Nirman Agri Genetics' (NSE:NIRMAN) Story Than Just Weak EarningsShareholders didn't appear too concerned by Nirman Agri Genetics Limited's ( NSE:NIRMAN ) weak earnings. We did some...
Reported Earnings • Jun 03Full year 2026 earnings released: EPS: ₹21.98 (vs ₹31.57 in FY 2025)Full year 2026 results: EPS: ₹21.98 (down from ₹31.57 in FY 2025). Revenue: ₹1.97b (down 17% from FY 2025). Net income: ₹176.1m (down 30% from FY 2025). Profit margin: 9.0% (down from 11% in FY 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (57% accrual ratio). Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Market cap is less than US$10m (₹389.7m market cap, or US$4.10m). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Paying a dividend despite having no free cash flows.
お知らせ • May 27Nirman Agri Genetics Limited to Report Q4, 2026 Results on May 30, 2026Nirman Agri Genetics Limited announced that they will report Q4, 2026 results on May 30, 2026
Buy Or Sell Opportunity • Apr 02Now 21% overvaluedOver the last 90 days, the stock has fallen 31% to ₹42.60. The fair value is estimated to be ₹35.31, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 78% over the last year. Earnings per share has grown by 38%.
Valuation Update With 7 Day Price Move • Dec 04Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₹71.05, the stock trades at a trailing P/E ratio of 2x. Average trailing P/E is 91x in the Biotechs industry in India. Total loss to shareholders of 82% over the past year.
分析記事 • Nov 28We Don’t Think Nirman Agri Genetics' (NSE:NIRMAN) Earnings Should Make Shareholders Too ComfortableInvestors appear disappointed with Nirman Agri Genetics Limited's ( NSE:NIRMAN ) recent earnings, despite the decent...
Reported Earnings • Nov 20First half 2026 earnings released: EPS: ₹18.20 (vs ₹16.46 in 1H 2025)First half 2026 results: EPS: ₹18.20 (up from ₹16.46 in 1H 2025). Revenue: ₹1.46b (up 30% from 1H 2025). Net income: ₹145.8m (up 27% from 1H 2025). Profit margin: 10.0% (in line with 1H 2025).
お知らせ • Nov 14Nirman Agri Genetics Limited to Report First Half, 2026 Results on Nov 14, 2025Nirman Agri Genetics Limited announced that they will report first half, 2026 results on Nov 14, 2025
Valuation Update With 7 Day Price Move • Nov 03Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹95.05, the stock trades at a trailing P/E ratio of 3x. Average trailing P/E is 104x in the Biotechs industry in India. Total loss to shareholders of 72% over the past year.
New Risk • Oct 29New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹843.4m (US$9.56m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.8% average weekly change). High level of non-cash earnings (97% accrual ratio). Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Market cap is less than US$10m (₹843.4m market cap, or US$9.56m). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (11% net profit margin).
Board Change • Oct 11High number of new directorsNon-Executive Director Sagar Chavan was the last director to join the board, commencing their role in 2025.
分析記事 • Oct 09A Piece Of The Puzzle Missing From Nirman Agri Genetics Limited's (NSE:NIRMAN) 31% Share Price ClimbNirman Agri Genetics Limited ( NSE:NIRMAN ) shareholders are no doubt pleased to see that the share price has bounced...
Valuation Update With 7 Day Price Move • Oct 02Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₹170, the stock trades at a trailing P/E ratio of 4.7x. Average trailing P/E is 61x in the Biotechs industry in India. Total loss to shareholders of 50% over the past year.
New Risk • Sep 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.2% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Profit margins are more than 30% lower than last year (11% net profit margin). Market cap is less than US$100m (₹1.12b market cap, or US$12.6m).
Buy Or Sell Opportunity • Sep 18Now 20% overvaluedOver the last 90 days, the stock has fallen 1.5% to ₹200. The fair value is estimated to be ₹166, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 65% over the last 3 years. Earnings per share has grown by 40%.
Valuation Update With 7 Day Price Move • Sep 12Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹164, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 63x in the Biotechs industry in India. Total loss to shareholders of 61% over the past year.
お知らせ • Sep 10Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2025Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2025, at 13:00 Indian Standard Time.
New Risk • Aug 24New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹872.7m market cap, or US$10.00m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Share price has been volatile over the past 3 months (7.3% average weekly change). Profit margins are more than 30% lower than last year (11% net profit margin).
New Risk • Aug 04New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹873.9m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹873.9m market cap, or US$9.97m). Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Profit margins are more than 30% lower than last year (11% net profit margin).
Valuation Update With 7 Day Price Move • Jul 30Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹148, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 55x in the Biotechs industry in India. Total loss to shareholders of 60% over the past year.
New Risk • Jul 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Profit margins are more than 30% lower than last year (11% net profit margin). Market cap is less than US$100m (₹1.05b market cap, or US$12.2m).
分析記事 • Jul 19Positive Sentiment Still Eludes Nirman Agri Genetics Limited (NSE:NIRMAN) Following 26% Share Price SlumpUnfortunately for some shareholders, the Nirman Agri Genetics Limited ( NSE:NIRMAN ) share price has dived 26% in the...
分析記事 • Jul 19Positive Sentiment Still Eludes Nirman Agri Genetics Limited (NSE:NIRMAN) Following 26% Share Price SlumpUnfortunately for some shareholders, the Nirman Agri Genetics Limited ( NSE:NIRMAN ) share price has dived 26% in the...
Buy Or Sell Opportunity • Jun 23Now 21% overvaluedOver the last 90 days, the stock has fallen 7.7% to ₹205. The fair value is estimated to be ₹169, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 65% over the last 3 years. Earnings per share has grown by 40%.
Valuation Update With 7 Day Price Move • Jun 10Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₹204, the stock trades at a trailing P/E ratio of 5.6x. Average trailing P/E is 49x in the Biotechs industry in India. Total returns to shareholders of 9.9% over the past year.
Board Change • May 14High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. MD & Director Pranav Bagal is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Apr 09Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹260, the stock trades at a trailing P/E ratio of 7.2x. Average trailing P/E is 48x in the Biotechs industry in India. Total returns to shareholders of 35% over the past year.
New Risk • Apr 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.7% average weekly change). Minor Risks Profit margins are more than 30% lower than last year (11% net profit margin). Market cap is less than US$100m (₹1.36b market cap, or US$15.9m).
分析記事 • Mar 29Investors Give Nirman Agri Genetics Limited (NSE:NIRMAN) Shares A 27% HidingTo the annoyance of some shareholders, Nirman Agri Genetics Limited ( NSE:NIRMAN ) shares are down a considerable 27...
Valuation Update With 7 Day Price Move • Mar 25Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹222, the stock trades at a trailing P/E ratio of 6.1x. Average trailing P/E is 52x in the Biotechs industry in India. Total returns to shareholders of 28% over the past year.
Buy Or Sell Opportunity • Mar 24Now 21% overvaluedOver the last 90 days, the stock has fallen 46% to ₹211. The fair value is estimated to be ₹175, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 65% over the last 3 years. Earnings per share has grown by 40%.
分析記事 • Mar 19Calculating The Intrinsic Value Of Nirman Agri Genetics Limited (NSE:NIRMAN)Key Insights Using the 2 Stage Free Cash Flow to Equity, Nirman Agri Genetics fair value estimate is ₹175 Current share...
Valuation Update With 7 Day Price Move • Mar 05Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹227, the stock trades at a trailing P/E ratio of 6.3x. Average trailing P/E is 47x in the Biotechs industry in India. Total returns to shareholders of 11% over the past year.
Valuation Update With 7 Day Price Move • Feb 12Investor sentiment deteriorates as stock falls 26%After last week's 26% share price decline to ₹263, the stock trades at a trailing P/E ratio of 7.3x. Average trailing P/E is 54x in the Biotechs industry in India. Total returns to shareholders of 1.2% over the past year.
分析記事 • Feb 12Nirman Agri Genetics Limited (NSE:NIRMAN) Stock's 28% Dive Might Signal An Opportunity But It Requires Some ScrutinyNirman Agri Genetics Limited ( NSE:NIRMAN ) shares have had a horrible month, losing 28% after a relatively good period...
New Risk • Feb 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Profit margins are more than 30% lower than last year (11% net profit margin). Market cap is less than US$100m (₹1.72b market cap, or US$19.8m).
New Risk • Feb 06New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 11% Last year net profit margin: 16% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (11% net profit margin). Market cap is less than US$100m (₹2.13b market cap, or US$24.3m).
Reported Earnings • Feb 06Third quarter 2025 earnings released: EPS: ₹8.40 (vs ₹5.60 in 3Q 2024)Third quarter 2025 results: EPS: ₹8.40 (up from ₹5.60 in 3Q 2024). Revenue: ₹610.7m (up 199% from 3Q 2024). Net income: ₹67.3m (up 101% from 3Q 2024). Profit margin: 11% (down from 16% in 3Q 2024). The decrease in margin was driven by higher expenses.
お知らせ • Jan 09+ 1 more updateNirman Agri Genetics Limited Announces the Resignation of Sandipan Baburao Bhawar as Chief Financial OfficerNirman Agri Genetics Limited informed that Mr. Sandipan Baburao Bhawar has tendered his resignation from the Post of Chief Financial Officer (CFO) and KMP of the Company effective from January 8, 2025 (after the closing of business hours) on account of reasons as mentioned in resignation letter attached herewith. The Company is in the process of appointing a new Chief Financial Officer and the same will be communicated to the Stock Exchange in due course.
分析記事 • Jan 08Should You Be Adding Nirman Agri Genetics (NSE:NIRMAN) To Your Watchlist Today?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Board Change • Jan 02High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. MD & Director Pranav Bagal is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 19High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. MD & Director Pranav Bagal is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 15Second quarter 2025 earnings released: EPS: ₹8.01 (vs ₹5.60 in 2Q 2024)Second quarter 2025 results: EPS: ₹8.01 (up from ₹5.60 in 2Q 2024). Revenue: ₹620.9m (up 204% from 2Q 2024). Net income: ₹64.2m (up 92% from 2Q 2024). Profit margin: 10% (down from 16% in 2Q 2024). The decrease in margin was driven by higher expenses.
お知らせ • Sep 27Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2024Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2024, at 12:00 Indian Standard Time.
Valuation Update With 7 Day Price Move • Sep 20Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹346, the stock trades at a trailing P/E ratio of 15.2x. Average trailing P/E is 36x in the Biotechs industry in India. Total returns to shareholders of 99% over the past year.
Reported Earnings • Aug 15First quarter 2025 earnings releasedFirst quarter 2025 results: EPS: ₹8.45. Net income: ₹50.4m (up ₹50.4m from 1Q 2024).
Valuation Update With 7 Day Price Move • Aug 14Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹439, the stock trades at a trailing P/E ratio of 25.2x. Average trailing P/E is 29x in the Biotechs industry in India. Total returns to shareholders of 219% over the past year.
分析記事 • Aug 13Here's Why We Think Nirman Agri Genetics (NSE:NIRMAN) Might Deserve Your Attention TodayThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Valuation Update With 7 Day Price Move • Jul 19Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹439, the stock trades at a trailing P/E ratio of 25.1x. Average trailing P/E is 49x in the Biotechs industry in India. Total returns to shareholders of 124% over the past year.
分析記事 • Jul 03Nirman Agri Genetics Limited (NSE:NIRMAN) Stock Rockets 47% But Many Are Still Ignoring The CompanyThe Nirman Agri Genetics Limited ( NSE:NIRMAN ) share price has done very well over the last month, posting an...
Valuation Update With 7 Day Price Move • Jul 01Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹249, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 44x in the Biotechs industry in India. Total returns to shareholders of 87% over the past year.
New Risk • Jun 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.6% average weekly change). Minor Risk Market cap is less than US$100m (₹1.10b market cap, or US$13.2m).
Valuation Update With 7 Day Price Move • Jun 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹185, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 44x in the Biotechs industry in India. Total returns to shareholders of 70% over the past year.
お知らせ • Jun 01Nirman Agri Genetics Limited to Report Second Half, 2024 Results on May 30, 2024Nirman Agri Genetics Limited announced that they will report second half, 2024 results on May 30, 2024
Reported Earnings • May 29Full year 2024 earnings released: EPS: ₹17.46 (vs ₹6.72 in FY 2023)Full year 2024 results: EPS: ₹17.46 (up from ₹6.72 in FY 2023). Revenue: ₹633.4m (up 121% from FY 2023). Net income: ₹104.0m (up 160% from FY 2023). Profit margin: 16% (up from 14% in FY 2023). The increase in margin was driven by higher revenue.
Valuation Update With 7 Day Price Move • Apr 22Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹223, the stock trades at a trailing P/E ratio of 33.2x. Average trailing P/E is 35x in the Biotechs industry in India. Total returns to shareholders of 204% over the past year.
お知らせ • Apr 19Nirman Agri Genetics Limited Receives License from Department of Agriculture, Government of TelanganaNirman Agri Genetics Limited informed to the Stakeholders that the Company has been granted with License from the Government of Telangana to carry on the business of a dealer in seeds for various purposes in the State of Telangana. It will help in expanding and tapping new geographical markets. This license will magnificently support to increase revenues. Name of the regulatory or licensing authority: Department of Agriculture, Government of Telangana. Brief details of the approval/license: The Company has been granted license to sell, export, import and store the Agriculture Seeds for the various purposes in the State of Telangana. Access to this License will help in dealing of Paddy seeds in the State of Telangana. Period for which such license is valid: 5 years (From February 26, 2024 to February 24, 2029).
Valuation Update With 7 Day Price Move • Mar 28Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹178, the stock trades at a trailing P/E ratio of 26.5x. Average trailing P/E is 32x in the Biotechs industry in India. Total returns to shareholders of 85% over the past year.
Valuation Update With 7 Day Price Move • Mar 13Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹190, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 33x in the Biotechs industry in India.
Valuation Update With 7 Day Price Move • Dec 12Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹258, the stock trades at a trailing P/E ratio of 38.4x. Average trailing P/E is 53x in the Biotechs industry in India.
Valuation Update With 7 Day Price Move • Oct 12Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹214, the stock trades at a trailing P/E ratio of 31.8x. Average trailing P/E is 32x in the Biotechs industry in India.
お知らせ • Sep 13Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2023Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2023, at 12:00 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone Financial Statements of the Company for the Financial Year ended 31st March, 2023 and the Reports of the Board of Directors and Auditors thereon; to Re-appoint Mr. Avinash Bhimrao Bagal, Non-Executive Non-Independent Director, who retires by rotation and being eligible, offers himself for re-appointment; to Approve the Appointment of M/s. Devendra C Belan & Associates, Chartered Accountants (ICAI Firm Registration Number: 126495W) as the Statutory Auditor of the Company for a period of 5 years; i.e. from the conclusion of this Annual General Meeting till the conclusion of Next Annual General Meeting from this Annual General Meeting; and to discuss other matters.
Valuation Update With 7 Day Price Move • Aug 24Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹178, the stock trades at a trailing P/E ratio of 26.5x. Average trailing P/E is 35x in the Biotechs industry in India.
New Risk • Aug 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹815.4m (US$9.85m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). High level of non-cash earnings (28% accrual ratio). Market cap is less than US$10m (₹815.4m market cap, or US$9.85m). Minor Risk Revenue is less than US$5m (₹286m revenue, or US$3.5m).
Valuation Update With 7 Day Price Move • Aug 07Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹161, the stock trades at a trailing P/E ratio of 24x. Average trailing P/E is 37x in the Biotechs industry in Asia.
Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹147, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 38x in the Biotechs industry in Asia.
Valuation Update With 7 Day Price Move • Jun 01Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹96.90, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 39x in the Biotechs industry in Asia.
Valuation Update With 7 Day Price Move • Apr 27Investor sentiment improves as stock rises 26%After last week's 26% share price gain to ₹76.75, the stock trades at a trailing P/E ratio of 17.9x. Average trailing P/E is 17x in the Biotechs industry in India.
Valuation Update With 7 Day Price Move • Apr 12Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹67.70, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 17x in the Biotechs industry in India.
Board Change • Mar 31High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. MD & Director Pranav Bagal is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.